Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Azd8205 – Application in Therapy and Current Clinical Research
Azd8205 – Aplicación en terapia e investigaciones clínicas actuales
AZD8205 for Endometrial Cancer Clinical Trial 2025 | Power
Structure of topoisomerase I inhibitors-based ADCs. A FDA-approved ADCs ...
Novel ADC AZD8205 demonstrates manageable safety profile and ...
Molecular structure of AZD1305. | Download Scientific Diagram
ESMO: Novel ADC AZD8205 demonstrates manageable safety profile and ...
ESMO 2024: Novel ADC AZD8205 demonstrates manageable safety profile and ...
AZD8205 Phase I/IIa Trial Result | ESMO 2024 | DelveInsight Business ...
2 The chemical structure of radiolabelled AZD1152-HQPA. | Download ...
Effect of AZD5305 on PARP2 retention on DNA. (A) The crystal structure ...
A Phase I/IIa Study of AZD8205 given alone or Combined, in Participants ...
Chemical structure of AZD3965. | Download Scientific Diagram
AZD8205 Phase I/IIa Trial Result | ESMO 2024
Structure of AZD2563. | Download Scientific Diagram
Chemical structure of (a) AZD2014 (b) AZD8055. | Download Scientific ...
Fatty Acid Chemical Structure Palmitic Acid Or Hexadecanoic, C16H32O2
AstraZeneca's AZD8205 Clinical Trial Application Approved
Emerging ADC Targets: B7-H3 and B7-H4
Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 ...
有效载荷（payload）的多样性：ADC药物未来开发的关键一环 - 脉脉
阿斯利康AZD批准8205临床试验申请-试药员招聘与临床试验信息平台
AZD8205（B7-H4 ADC）联合AZD5305的临床前研究 - 平头哥
2024年ESMO：抗体偶联药AZD8205 的首次人体临床试验数据公布，多个肿瘤类型迎来新希望！医药新闻-ByDrug-一站式医药资源共享 ...
阿斯利康 B7-H4 ADC 国内临床即将启动！中国研发提速中_药物_Enhertu_研究
Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody ...
Puxitatug samrotecan drug-linker (AZD8205 drug-linker) | Drug-Linker ...
Distinct Structural Mechanisms for Inhibition of Pyruvate Dehydrogenase ...
AZD-8205(AZD-8205) - 药物靶点：B7-H4 x Top I_在研适应症：恶性实体肿瘤，转移性子宫内膜恶性肿瘤，晚期恶性实体 ...
puxitatug samrotecan (AZD8205) / AstraZeneca
Adenosine triphosphate-competitive mTOR inhibition suppresses T cell ...
【AACR 2023】ADC药物”角力”AACR-自主发布-资讯-生物在线
Datroway (Datopotamab Deruxtecan-dlnk for Injection): Side Effects ...
AZD8205-hIgG1 - Kyinno Bio
Puxitatug samrotecan (AZD 8205) | ADC | MedChemExpress
Computational Study on New Natural Compound Inhibitors of Pyruvate ...
AZD-8205(AZD-8205) - 药物靶点：B7-H4 x Top I_在研适应症：子宫内膜癌，恶性实体肿瘤，转移性子宫内膜恶性肿瘤 ...
阿斯利康：自研 B7-H4 ADC 国内启动临床_Insight_药物_包括
606O Initial results from a first-in-human study of the B7-H4-directed ...
B7-H4 ADC AZD8205，首次披露临床结果_Insight_患者_治疗
AZD8055 | mTOR Pathway Inhibitor | STEMCELL Technologies
Anti-B7-H4(AZD-8205 biosimilar) mAb-B7-H4 Biosimilar mAb for ELISA-DIMA ...
Chemical structures of AZD1775 and PD0166285. Chemical structures of ...
Structure, biochemical, and cellular activity of AZD2014. A, chemical ...
mTOR抑制剂(AZD8055)
AZD8421 | CDK inhibitor | CAS 3047321-53-6 | Selleck
子宫内膜癌新药临床试验：ADC药物Puxitatug Samrotecan（AZD8205）-印塔健康官网
2024年ESMO：抗体偶联药AZD8205 的首次人体临床试验数据公布，多个肿瘤类型迎来新希望！-MedSci.cn
Schematic of AZD0466 drug substance and drug product process. A ...
医药魔方
ISSX 2022 - Hypha Discovery
Overlay of substructure of RBD/AZD8895 in RBD/AZD8895/AZD1061 complex ...
靶向B7-H4，新型ADC药物AZD8205 在HR+/HER2–晚期乳腺癌临床研究中显疗效 - MedFind
Small-molecule Articles | Smolecule
Structures and atom numbering of the studied compounds, and the ...
Schematic representation of the AZD2 molecular structure. | Download ...
中美合作！抗癌新藥AZD8205有效治療癌症得到證實！ - 每日頭條
AZD-8205(AZD-8205) - 药物靶点：B7-H4 x Top I_在研适应症：晚期恶性实体瘤，胆管癌，胆道癌_专利_临床_研发
AZD8055 is an ATP-competitive mTOR kinase inhibitor. A, chemical ...
Safety and preliminary efficacy of puxitatug samrotecan (AZD8205) in ...
AZD-5462 | Selleck Chemicals
Anti-B7-H4(AZD-8205 biosimilar) mAb
Abstract 1765: Discovery and first disclosure of AZD8205, a B7-H4 ...
Saruparib (AZD5305) | PARP inhibitor | Mechanism | Concentration
2024年ESMO：抗体偶联药AZD8205 的首次人体临床试验数据公布，多个肿瘤类型迎来新希望！_腾讯新闻
【重磅】晚期子宮內膜癌治療新突破！AZD8205 ADC療法疾病控制率超80% - 藥時事 Drugnews (@drugnews) | Dcard
2024年ESMO：抗体偶联药AZD8205 的首次人体临床试验数据公布，多个肿瘤类型迎来新希望！ - 知乎
AZD-PEG2-azide | Biochemical Assay Reagent | MedChemExpress
ADC药物之Payload简介_adc的payload-CSDN博客
B7家族的泛癌种新星：B7-H4 - 知乎
AZD6370 | MedChemExpress
AZD8055 CAS#: 1009298-09-2
重压双抗ADC后，阿斯利康收购亘喜生物，布局双靶点CAR-T - 知乎
阿斯利康自研ADC崛起_患者_Elahere_药物
Small molecules shield mice against hearing loss
阿斯利康自研ADC崛起? - 知乎
